Awarded Contractocds-h6vhtk-051c98

NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026

Name: NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026
Creator: NHS England
Published: 2026-03-17T12:14:24.000Z

NHS Branded Framework Agreement – Lot 1 - Tranche A for the North of England and Midlands & East. Period of Framework Agreement: 1st September 2026 to 31st August 2028 with an option or option(s) to extend (at the authority’s discretion for a further 24 months. Lot 2 - Natalizumab for London and South of England. The period of Framework Agreement: 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.

Buyer

NHS England

Value

£700,702,136

Published

17 Mar 2026

Closes

17 Apr 2026

Procurement details

Source

Find a Tender

Region

Lambeth

Procurement method

Open

CPV classifications

33600000

Pharmaceutical products

Lots

Lot 1 CM/PHR/25/5730/01 - Tranche B for NOFE and MAE

£846,138,512

Lot 1 - Tranche A for the North of England and Midlands & East. Period of Framework Agreement: 1st September 2026 to 31st August 2028 with an option or option(s) to extend (at the authority’s discretion for a further 24 months.

Delivery: UKC · United Kingdom, UKD · United Kingdom, UKF · United Kingdom, UKG · United Kingdom, UKH · United Kingdom, UKI · United Kingdom

Lot 2 CM/PHR/25/5730/02 - Natalizumab for London & SOFE

£31,532,058

Lot 2 - Natalizumab for London and South of England. The period of Framework Agreement : 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.

Delivery: UKC · United Kingdom, UKD · United Kingdom, UKF · United Kingdom, UKG · United Kingdom, UKH · United Kingdom, UKI · United Kingdom

Not provided

Bidding documents · Word document

Contains public sector information licensed under the Open Government Licence v3.0.